BPB Reports
Online ISSN : 2434-432X
Regular Article
Effects of Keishi-Bukuryo-gan-ka-Yokuinin on Rosacea Model Mice
Natsu WatanabeWataru MatsunagaAkinobu Gotoh
Author information
JOURNAL OPEN ACCESS FULL-TEXT HTML

2022 Volume 5 Issue 6 Pages 147-153

Details
Abstract

Rosacea is an intractable skin disease and no effective treatment has been established, but there are cases of improvement with Kampo medicine. In this study, the efficacy of Keishi-Bukukryo-gan-ka-Yokuinin (KBY) in ameliorating the symptoms of rosacea was investigated in a steroid-induced rosacea mouse model. The mice were fed a KBY-containing diet for 28 d, after application of clobetasol propionate for 10 d; thereafter, the velocity of capillary blood flow, area of the skin purpura, histopathologic features, and gut microbiota were analyzed. The KBY-fed mice showed remarkable recovery in the capillary blood flow velocity and purpura area, as well as restoration of the epidermis features. Furthermore, gut microbiome analysis showed the enhancement of Lactobacillus population in the KBY-fed mice. The KBY-induced improvement of circulatory disturbances in skin might contribute to the alleviation of telangiectasia and erythema. Lactobacillus may be involved in alleviating the rosacea-like symptoms in association with KBY; however, this association should be investigated further by using other analysis methods. Our results provide evidence of the effectiveness of KBY in improving the pathology of rosacea.

Content from these authors
© 2022 The Pharmaceutical Society of Japan

BPB Reports applies the Creative Commons Attribution (CCBY) license to works we published. The license was developed to facilitate open access - namely, free immediate access to, and unrestricted reuse of, original works to all types. Under this license, authors agree to make articles legally available for reuse, without permissions of fees, for virtually any purpose. Anyone may copy, distribute, or reuse these articles, as long as the author and original source are properly cited.
https://creativecommons.org/licenses/by/4.0/
Previous article Next article
feedback
Top